Literature DB >> 14668801

BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency.

Carla Oliveira1, Mafalda Pinto, Alex Duval, Caroline Brennetot, Enric Domingo, Eloi Espín, Manel Armengol, Hiroyuki Yamamoto, Richard Hamelin, Raquel Seruca, Simó Schwartz.   

Abstract

Genes from the RAF family are Ras-regulated kinases involved in growth cellular responses. Recently, a V599E hotspot mutation within the BRAF gene was reported in a high percentage of colorectal tumors and significantly associated to defective mismatch repair (MMR). Additionally, BRAF mutations were described only in K-Ras-negative colon carcinomas, suggesting that BRAF/K-Ras activating mutations might be alternative genetic events in colon cancer. We have addressed to what extent the tumorigenic-positive selection exerted by BRAF mutations seen in colorectal MMR-deficient tumors was also involved in the tumorigenesis of gastric cancer. Accordingly, BRAF mutations were detected in 34% (25/74) of colorectal MMR-deficient tumors and in 5% (7/142) of MMR-proficient colorectal cases (P=0.0001). All mutations found in the MSI cases corresponded to the previously reported hotspot V599E. Two D593K and a K600E additional mutations were also detected in three MSS cases. However, only one mutation of BRAF was found within 124 MSS gastric tumors and none in 37 MSI gastric tumors, clearly suggesting that BRAF mutations are not involved in gastric tumorigenesis. Nonetheless, a high incidence of mutations of K-Ras was found within the MSI gastric group of tumors (P=0.0005), suggesting that the activation of K-Ras-dependent pathways contributes to the tumorigenesis of gastric cancers with MMR deficiency. Accordingly, our results show evidences that BRAF mutations characterize colon but not gastric tumors with MMR deficiency and are not involved in the tumorigenesis of gastric cancer of the mutator phenotype pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668801     DOI: 10.1038/sj.onc.1207061

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  59 in total

Review 1.  Lynch syndrome diagnostics: decision-making process for germ-line testing.

Authors:  E Lastra; M García-González; B Llorente; C Bernuy; M J Barrio; L Pérez-Cabornero; M Durán; C García-Girón
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

Review 2.  BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies.

Authors:  Callisia N Clarke; E Scott Kopetz
Journal:  J Gastrointest Oncol       Date:  2015-12

3.  KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity.

Authors:  Pedro Queirós; Hugo Pinheiro; Joana Carvalho; Patrícia Oliveira; Irene Gullo; Fátima Carneiro; Gabriela M Almeida; Carla Oliveira
Journal:  Virchows Arch       Date:  2015-08-29       Impact factor: 4.064

Review 4.  Colorectal cancer: a model for epigenetic tumorigenesis.

Authors:  J J L Wong; N J Hawkins; R L Ward
Journal:  Gut       Date:  2006-07-13       Impact factor: 23.059

5.  Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: correlation with ancestry markers.

Authors:  Nathália C Campanella; Gustavo N Berardinelli; Cristovam Scapulatempo-Neto; Danilo Viana; Edenir I Palmero; Rui Pereira; Rui M Reis
Journal:  Eur J Hum Genet       Date:  2013-11-06       Impact factor: 4.246

6.  BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents.

Authors:  Xuening Wang; Jonathan S Harrison; George P Studzinski
Journal:  J Steroid Biochem Mol Biol       Date:  2016-09-13       Impact factor: 4.292

Review 7.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

Review 8.  Evolving role of gene expression signatures as biomarkers in early-stage colon cancer.

Authors:  Gaurav Goel
Journal:  J Gastrointest Cancer       Date:  2014-12

Review 9.  Molecular dissection of microsatellite instable colorectal cancer.

Authors:  Eduardo Vilar; Josep Tabernero
Journal:  Cancer Discov       Date:  2013-03-01       Impact factor: 39.397

10.  Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.

Authors:  Ana Preto; Joana Gonçalves; Ana P Rebocho; Joana Figueiredo; Ana M Meireles; Ana S Rocha; Helena M Vasconcelos; Hugo Seca; Raquel Seruca; Paula Soares; Manuel Sobrinho-Simões
Journal:  BMC Cancer       Date:  2009-10-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.